| Expression pattern: |
UP |
| Associated gene: |
VEGFA, KDR, FLT4 |
| Associated microRNA: |
miR-665 |
| Biological function: |
promotes ovarian cancer cell proliferation and invasion; promotes tumor growth, angiogenesis, and lymphangiogenesis |
| Molecular mechanism: |
ceRNA mechanism: circASH2L sponges miR-665 to upregulate VEGFA |
| Biological pathway or process: |
proliferation (promotes); invasion (promotes); angiogenesis (promotes); metastasis (other); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Sanger Sequencing; FISH / smFISH; Luciferase Reporter Assay; Western Blot; Transfection; CCK8; EdU Staining; Transwell Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Tube Formation Assay; Clinical Sample Validation; Bioinformatics Analysis |
| Clinical significance: |
circASH2L expression was associated with tumor size, lymph node metastasis, and FIGO stage |
| Description: |
circASH2L is up-regulated in ovarian cancer tissues and cell lines and acts as an oncogenic circRNA. It mainly localizes to the cytoplasm and functions as a ceRNA to sponge miR-665, thereby increasing VEGFA expression and promoting proliferation, invasion, as well as VEGFA-mediated angiogenesis and lymphangiogenesis in vitro and in xenograft tumors. |
| Confidence score: |
0.8174 |